FDA Biologics (BLA & Biosimilars)Original article
FDA Proposes Framework to Advance Credibility of AI Models Used for Drug and Biological Product Submissions
RegulatoryPositive
AI Analysis
Summary
The FDA issued draft guidance providing recommendations on the use of artificial intelligence in regulatory submissions for drug and biological products to support safety, effectiveness, and quality assessments.
Outcome Details
Draft guidance issued on AI model credibility for drug and biological product submissions
Importance:4/10
Sentiment:
0.30
AI/Machine LearningRegulatory FrameworkDraft GuidanceDrug SubmissionsBiological Products
Read the original article
Published by FDA Biologics (BLA & Biosimilars) on September 1, 2026 1:50 PM